Open Access

Leucine‑rich repeat‑containing G protein‑coupled receptor 5 and CD133 expression is associated with tumor progression and resistance to preoperative chemoradiotherapy in low rectal cancer

  • Authors:
    • Yuzo Harada
    • Shinsuke Kazama
    • Teppei Morikawa
    • Koji Murono
    • Koji Yasuda
    • Kensuke Otani
    • Takeshi Nishikawa
    • Toshiaki Tanaka
    • Tomomichi Kiyomatsu
    • Kazushige Kawai
    • Keisuke Hata
    • Hiroaki Nozawa
    • Hironori Yamaguchi
    • Soichiro Ishihara
    • Toshiaki Watanabe
  • View Affiliations

  • Published online on: October 18, 2017     https://doi.org/10.3892/ol.2017.7207
  • Pages:7791-7798
  • Copyright: © Harada et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: PDF 0 views | HTML 0 views
0

Abstract

Preoperative chemoradiotherapy has been performed as a standard therapy for advanced low rectal cancer. Cancer stem cells (CSCs) have been reported to contribute to resistance to treatment and patient prognosis. Leucine‑rich repeat‑containing G protein‑coupled receptor 5 (LGR5) and cluster of differentiation (CD133) are putative markers for CSCs. However, their prognostic ability remains unknown, and evaluation of a single marker can be insufficient due to the heterogeneity of cancer. LGR5 and CD133 expression was immunohistochemically evaluated in surgical specimens of 56 patients who received curative resection following chemoradiotherapy for advanced low rectal cancer. In addition, the correlations between their expression levels, and clinicopathological features and patient prognosis were asessed. LGR5 expression was significantly correlated with lymphatic invasion, lymph node metastasis, and tumor node metastasic (TNM) stage. CD133 expression was significantly correlated with vascular invasion and the tumor regression grade. Combined expression was significantly correlated with lymphatic invasion, tumor regression grade and TNM stage, but not with overall, and disease‑free survival. LGR5 and CD133 expressions may represent useful markers associated with tumor progression and resistance to chemoradiotherapy in patients with low rectal cancer. Furthermore, combined expression of these markers may be a more useful marker compared with the expression of each single marker.

Related Articles

Journal Cover

December 2017
Volume 14 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Harada, Y., Kazama, S., Morikawa, T., Murono, K., Yasuda, K., Otani, K. ... Watanabe, T. (2017). Leucine‑rich repeat‑containing G protein‑coupled receptor 5 and CD133 expression is associated with tumor progression and resistance to preoperative chemoradiotherapy in low rectal cancer. Oncology Letters, 14, 7791-7798. https://doi.org/10.3892/ol.2017.7207
MLA
Harada, Y., Kazama, S., Morikawa, T., Murono, K., Yasuda, K., Otani, K., Nishikawa, T., Tanaka, T., Kiyomatsu, T., Kawai, K., Hata, K., Nozawa, H., Yamaguchi, H., Ishihara, S., Watanabe, T."Leucine‑rich repeat‑containing G protein‑coupled receptor 5 and CD133 expression is associated with tumor progression and resistance to preoperative chemoradiotherapy in low rectal cancer". Oncology Letters 14.6 (2017): 7791-7798.
Chicago
Harada, Y., Kazama, S., Morikawa, T., Murono, K., Yasuda, K., Otani, K., Nishikawa, T., Tanaka, T., Kiyomatsu, T., Kawai, K., Hata, K., Nozawa, H., Yamaguchi, H., Ishihara, S., Watanabe, T."Leucine‑rich repeat‑containing G protein‑coupled receptor 5 and CD133 expression is associated with tumor progression and resistance to preoperative chemoradiotherapy in low rectal cancer". Oncology Letters 14, no. 6 (2017): 7791-7798. https://doi.org/10.3892/ol.2017.7207